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Abstract
Mutation of the melanocortin-receptor 4 (MC4R) is the most frequent cause of severe obesity in humans. Binding of agouti-
related peptide (AgRP) to MC4R involves the co-receptor syndecan-3, a heparan sulfate proteoglycan. The proteoglycan can
be structurally modified by the enzyme heparanase. Here we tested the hypothesis that heparanase plays a role in food
intake behaviour and energy balance regulation by analysing body weight, body composition and food intake in genetically
modified mice that either lack or overexpress heparanase. We also assessed food intake and body weight following acute
central intracerebroventricular administration of heparanase; such treatment reduced food intake in wildtype mice, an effect
that was abolished in mice lacking MC4R. By contrast, heparanase knockout mice on a high-fat diet showed increased food
intake and maturity-onset obesity, with up to a 40% increase in body fat. Mice overexpressing heparanase displayed
essentially the opposite phenotypes, with a reduced fat mass. These results implicate heparanase in energy balance control
via the central melanocortin system. Our data indicate that heparanase acts as a negative modulator of AgRP signaling at
MC4R, through cleavage of heparan sulfate chains presumably linked to syndecan-3.
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Introduction
Obesity and overweight continue to increase world-wide, with
severe health consequences that pose heavy economic burdens on
society [1]. The balance between food intake and energy
expenditure is monitored and tightly regulated by the central
nervous system. The hypothalamus integrates afferent information
from metabolic and hunger/satiety signals with diverse brain
circuits involved in ingestive behaviour as well as energy
expenditure. Within the hypothalamus, the melanocortin system
represents a crucial point of convergence for these signals and is
therefore of primary importance for the regulation of body weight
[2,3,4]. The melanocortin receptor ligands, a-melanocyte stimu-
lating hormone (a-MSH) and agouti-related peptide (AgRP),
modulate downstream homeostatic signaling via their action at
melanocortin receptors MC3R and MC4R. The agonist a-MSH
reduces appetite and increases energy expenditure [4]. These
effects are opposed by AgRP, an obesity-inducing peptide that
operates as an inverse agonist at MC4R in vitro and in vivo [5]. Mice
and humans that lack a-MSH or have defective MC4R signaling
are hyperphagic, obese and show increased linear growth [6,7,8].
Conversely, ablation of AgRP neurons in adult mice causes acute
anorexia [9] whereas mice that overexpress AgRP become obese
[10]. AgRP deficient mice have a more subtle energy balance
disturbance with a late-onset lean phenotype [11]. In humans, a
defective MC4R is the most common cause of inherited severe
obesity [12].
The binding of AgRP to MC4R is facilitated by syndecan-3, a
heparan sulfate proteoglycan (HSPG) that appears to operate as a
co-receptor [13]. The HS polysaccharide side chains of HSPGs
provide binding epitopes for numerous proteins, and thus serve as
co-receptors for various ligands to enable fine-tuning of signals
[14,15]. Importantly, HS was found to directly bind AgRP but not
a-MSH [16]. Hypothalamic syndecan-3 has been implicated in
energy balance regulation [13,16,17,18] and is up-regulated
during fasting [16]. Indeed, mice that lack syndecan-3 have a
reduced fat mass and are protected against diet-induced obesity
[17].
Heparanase selectively cleaves HS chains at glucuronidic
linkages [19], and thus affects a variety of physiological and
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signalling [20]. Inspired by the potential importance of syndecan-3
HSPG in central melanocortin signaling [20] we sought to
determine whether heparanase has a role in energy balance. Our
studies explored genetic mouse models of altered heparanase
expression that either lack [21] or overexpress [22] heparanase,
along with experiments in which recombinant heparanase was
administered into the brain ventricles. The results indicate that
heparanase inhibits obesity by degrading HS chains, presumably
linked to syndecan-3, thereby suppressing the binding of AgRP to
MC4R.
Results
Heparanase knockout mice develop maturity-onset
obesity and have altered feeding responses
Previous analysis of the heparanase knockout (Hpa-ko) mice
showed neither remaining enzyme protein nor detectable catalytic
activity in any of the tissues analysed [21]. The body weight of
male Hpa-ko mice kept on normal chow was similar to that of wt
siblings for the first 5–6 weeks of life but diverged thereafter. Hpa-
ko mice weighed more than their wt siblings (Fig. 1A). Hpa-ko and
congenic wt siblings were subjected to DEXA analysis of body
composition at 21 weeks of age. Results showed that the difference
in body weight was largely due to a substantial increase in fat mass
in Hpa-ko mice, along with a smaller but significant increase in
lean body mass (Fig. 1B). Notably, the fat content of the Hpa-ko
lacking heparanase was almost twice that of wt controls. There was
no difference in body length.
To investigate food consumption, individually housed adult
male mice were given the choice between a low-fat and a high-fat
diet for one week. Hpa-ko mice consumed significantly more of the
high-fat diet and showed a higher overall energy intake than the wt
controls (Fig. 1C, right panel). Neither the intake of low-fat diet
(Fig. 1C, right panel) nor the intake of normal chow (with even lower
fat content) when offered alone (Fig. 1C, left panel) differed between
groups.
Effects of heparanase overexpression on body
composition, feeding response and energy metabolism
Over-expression of heparanase in the Hpg-tg mice was
confirmed immunocytochemically, with marked expression in
many brain areas, including the hypothalamus (Fig. S1). The Hpa-
tg mice showed a striking metabolic phenotype. DEXA analysis of
Hpa-tg mice at 5 months of age revealed reduced fat mass, but no
difference in lean body mass or body weight. Body length was
significantly increased compared to wt controls (Fig. 2A). Unex-
pectedly, cumulative food intake monitored over a period of one
week was significantly higher in the Hpa-tg group. Consumption of
normal chow by individually housed animals was monitored once
a day. Hpa-tg mice ate more chow than wt controls (Fig. 2B),
indicating decreased food efficiency. Bomb calorimetry measure-
ments revealed no difference in energy contents of faeces from
Hpa-tg and wt animals (Fig. S2), hence excluding energy loss in
faeces as a cause of the decreased food efficiency. However,
analysis of energy metabolism by indirect calorimetry (Fig. 2C)
showed that whereas Hpa-tg mice equalled wt energy expenditure,
they shifted towards a lower RQ during the dark phase. The
transgenic mice thus appear more prone to use fat as an energy
Figure 1. Increased body weight, altered body composition and food intake of Hpa-ko mice. (A) Increased body weight at maturity onset
of Hpa-ko mice. Male Hpa-ko mice kept on normal chow showed increased body weight compared to wt sibling controls, discernible from 10 weeks
of age (wt, n=7; Hpa-ko, n=20) and more pronounced at 15 weeks of age (wt, n=5; Hpa-ko, n=17). (B) Increased fat mass and lean body mass of
Hpa-ko mice. DEXA analysis of 21-week old animals showed larger fat mass and lean body mass in Hpa-ko mice (n=7) than in controls (n=4). There
was no difference in body length. (C) Increased food intake of Hpa-ko mice on high-fat diet but not on normal chow. Hpa-ko and wt control mice, age
10–15 weeks, were given either normal chow (left panel) or offered a choice between low-fat diet and high-fat diet during one week (right panel). No
difference was seen between the two groups (wt, n=6; Hpa-ko, n=7) on normal chow. Hpa-ko mice (n=7) ate significantly more of the high-fat diet
(expressed as kcal/one week; p=0.04) and more overall (p=0.019) than wt controls (n=5), whereas consumption of low-fat diet did not differ
significantly between the groups.
doi:10.1371/journal.pone.0034313.g001
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of relevant genes showed only marginal effects of heparanase
overexpression on Synd-3 and Pomc, but significantly decreased
hypothalamic expression of AgRP, compared to wt controls (Fig.
S3).
Intracerebroventricular injection of heparanase reduces
food intake and body weight gain after fasting
According to the current hypothesis cell-surface HS promotes
binding of AgRP to MC4R [13]. Truncation of these chains by
heparanase would favour receptor binding of the agonist a-MSH
and hence, cause a suppression of food intake. This hypothesis was
tested in acute experiments involving injection of recombinant
human heparanase into the lateral third dorsal ventricle along with
a starvation-refeeding protocol. Intracerebro-ventricular (ICV)
administration of heparanase caused a dramatic reduction in food
intake compared to vehicle-treated control mice. Cumulative food
intake at 6 hr after heparanase injection (and start of refeeding)
was less than 50% of that observed in controls (Fig. 3A, left panel).
This effect of heparanase injection was also evident in terms of
body weight gain that was only 30% of control after 6 hr and still
depressed after 24 hr (Fig. 3A, right panel).
Experiments designed to elucidate the time course of hepar-
anase action revealed different temporal windows depending on
when the enzyme was administered relative to the start of
refeeding. When access to food was admitted immediately after
heparanase injection, reflex hyperphagia was observed without
any discernible difference between heparanase- and vehicle-
treated groups during the first hour (Fig. 3B, left panel). Instead,
the reduction in food intake developed gradually during the
following hours, was most conspicuous 4–6 hr after enzyme
administration, and persisted well beyond the time window
required for control mice to resume normal feeding behaviour.
Importantly, this finding suggests that heparanase affects food
intake per se and not only in connection with reflex hyperphagia.
We next investigated whether the delayed response was inherent
to the mechanism triggered by the enzyme, alternatively, it could
also be explained by pharmacokinetic factors. We therefore
redesigned the experiment by administering the heparanase 1 hr
prior to food presentation. Under these conditions the reduction in
food intake was seen from the outset (Fig. 3B, right panel). The
delayed action observed after simultaneous heparanase injection
and food administration thus appears to reflect the time required
for the enzyme to reach and act on the HSPG target.
Collectively, these results implicate heparanase in the modula-
tion of MC4R signaling. To test this concept we designed a cross-
over study in which food intake was measured in MC4R male
knockouts and their wt siblings injected ICV with heparanase or
vehicle. The results showed that wt mice injected with heparanase
had 20–25% lower cumulative food intake 2 hr and 4 hr after
food presentation compared to vehicle controls, whereas there was
no effect of heparanase treatment in the MC4R knockout mice
(Fig. 4). The acute effects of centrally administered heparanase on
food intake can therefore be directly linked to modulation of
MC4R signaling. We also infer that the appetite suppression in the
wt mice was not due to general malaise/sickness induced by the
heparanase injection.
Discussion
Heparanase is an important endogenous regulator of
energy balance
Heparanase affects a variety of physiological and pathophysi-
ological processes, essentially through cleavage of HS chains on
HSPGs at cell surfaces or in the extracellular matrix [23]. Detailed
analysis of the Hpa-tg mouse strain used in this study showed that
cerebral expression of the enzyme led to degradation of HS,
accompanied by change in disaccharide composition (X. Zhang,
personal communication). Our results implicate heparanase with
regulation of energy balance, through modulation of MC4R
signaling. Male Hpa-ko mice display maturity-onset obesity and
exhibit increased food intake when given access to a high-fat diet.
Figure 2. Reduced fat mass but increased food intake by Hpa-tg mice. (A) Body weight and body composition determined by DEXA analysis
of Hpa-tg mice (n=9) and wt controls (n=8), age 12 weeks. No significant differences in lean body mass or body weight were detected, whereas the
Hpa-tg mice showed reduced fat mass, and increased body length (nose-anus measurement). (B) Increased food intake by Hpa-tg (n=5) compared to
wt control mice (n=4) during one week on normal chow. These animals were 36–37 weeks old, thus older than the mice tested in Fig. 1C. Mice were
individually housed and weighed before and after the experiment. (C) Indirect calorimetry measurements on the animals (27 weeks old) showed no
difference in energy expenditure (left panel) but a marked tendency toward lower RQ (right panel, p=0.09 based on areas under the curves) for Hpa-
tg mice.
doi:10.1371/journal.pone.0034313.g002
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over, central administration of heparanase lead to reduced food
intake in mice and this effect was abolished in mice lacking
MC4R.
The first observation associating a HSPG with appetite
regulation was maturity-onset obesity in transgenic mice over-
expressing syndecan-1 [16]. The constituent HS chains were
assumed to promote binding of AgRP to its receptor, MC4R, thus
stimulating food intake and at the same time precluding the
appetite-suppressing effects of a-MSH. This co-receptor function
would normally be exerted by syndecan-3, the predominant
HSPG isoform in the hypothalamus. Notably, a polymorphism in
the syndecan-3 gene has been associated with obesity in a female
population [24]. The levels of syndecan-3 and hence, exposure of
HS chains, at the cell surface, appear regulated through shedding
of the HS-substituted ectodomain by protease cleavage and vary
with the feeding state of the animal. It was proposed that the
shedding enzyme that cleaves hypothalamic syndecan-3 does not
recognize syndecan-1 [13,16,17,18].
Heparanase provides an alternative mechanism for modulating
accessibility of HS chains. Our results indicate that heparanase
affects energy balance, in particular, as a negative modulator of
AgRP signaling, by cleavage of HS chains on the syndecan-3 co-
receptor (Fig. 5). Hpa-ko mice thus develop a phenotype
reminiscent of that observed in syndecan-1 over-expressing mice
[16], with maturity-onset increase in body weight due to increased
fat and, to a lesser extent, lean body mass (Figs. 1A, B). Regulation
of food intake is affected as shown by increased intake of high-fat
chow (Fig. 1C). Conversely, heparanase over-expressing Hpa-tg
mice showed reduced fat mass, in seemingly logical contrast to the
Hpa-ko phenotype (Fig. 2A). The predicted mechanism was
corroborated by acute injections of heparanase directly into the
lateral cerebral ventricle, in connection with fasting-refeeding
experiments. This treatment resulted in a marked, sustained
suppression of food intake (Fig. 3) that was dependent upon intact
MC4R function (Fig. 4). Thus, the increased food intake of Hpa-ko
mice may be ascribed to more efficient AgRP co-receptor function
of HS chains (Fig. 5).
Heparanase is involved in multiple facets of energy
balance regulation
The MC4R signaling system is known to modulate multiple
factors in regulation of energy balance [20], and the seemingly
unified picture outlined through the Hpa-ko and Hpa-tg models in
Fig. 5 appears partly oversimplified. Heparanase affects a number
of distinct factors in energy balance regulation. Key components of
this equation are energy intake through feeding and energy
expenditure through basal metabolism, physical activity and
adaptive thermogenesis [2]. Unexpected effects of heparanase
overexpression may be ascribed to the complex regulatory
mechanisms behind this balance. Hpa-tg males thus were
unexpectedly found to eat more than wt controls (Fig. 2B), in
spite of their reduced fat mass (Fig. 2A). Whereas there was no
significant difference in energy expenditure, the Hpa-tg mice
showed a lower nominal RQ indicating a relative preference for
Figure 3. Intracerebroventricular injection of heparanase
reduced food intake and body weight gain after fasting. (A)
Effect on food intake. C57BL/6J mice (6–8 weeks old) with cannulae
inserted for the ICV experiment were fasted for 16 hr, and were then
subjected to ICV injection of recombinant heparanase as described in
Methods. The mice were allowed access to normal chow immediately
after injection, and food intake was measured over the subsequent 6 hr
period. The heparanase-treated mice (n=6) showed a .50% reduction
in cumulative food intake, related to body weight, compared to
controls (injection of vehicle; n=6). The same mice were weighed at
different time points following ICV injections. Reduction in body weight
gain of heparanase injected mice, compared to controls, was most
apparent after 6 hr, still discernible after 24 hr, but not detectable after
72 hr. (B) Time course of effects due to ICV heparanase injection. Four
experimental groups were designed: (1) heparanase-injected mice
(n=4) and (2) vehicle-injected mice (n=4) with immediate access to
food (left panel); (3) heparanase-injected mice (n=9) and (4) vehicle-
injected mice (n=5) given access to food 1 hr after the injection (right
panel). Determination of chow consumption (expressed as kcal/g body
weight) after the indicated time periods showed sustained reduction of
food intake for groups (1) and (3) compared to the respective control
groups (2) and (4). However, data restricted to the first hour of food
access showed a significant difference only between groups (3) and (4)
(p=0.0046), not between groups (1) and (2) (p=0.417).
doi:10.1371/journal.pone.0034313.g003
Figure 4. The acute effects of heparanase are mediated
through the MC4R. MC4r-ko mice and wt siblings (6–8 weeks old)
were subjected to the fasting-refeeding procedure, with ICV injection of
1.4 mg heparanase in a volume of 1 ml (n=8 and n=6, respectively) or
vehicle (n=6 and n=7, respectively) 1 h before access to food. The
heparanase injection of wt mice resulted in significant reduction in
cumulative food intake, 2 hr (p=0.023) and 4 hr (p=0.0053) after
refeeding, compared to vehicle-injected mice. Heparanase had no effect
on the MC4r-ko mice.
doi:10.1371/journal.pone.0034313.g004
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expression of the Hpa-tg mice (Fig. S3) is of particular significance
in this context, as central melanocortin signaling also controls
peripheral nutrition partitioning that may affect the amount of
body fat independently of food intake [25]. In fact, AgRP-ko mice,
a predicted phenotype mimic of our Hpa-tg animals (see Fig. 5)
showed increased fat utilization [11]. The Hpa-tg mice appear
more aggressive at adult age than wt controls but otherwise show
no apparent deviation in behaviour. Overall, our data indicate
that heparanase affects food intake primarily in a short-term
perspective and energy balance over a longer time span. It thus has
been suggested that AgRP acts both as an antagonist of the MC4R
and as an inverse agonist on its own, and that the different modes
of signaling relate to short-term effects of fasting and more long-
term effects on energy balance regulation, respectively [17]. We
therefore surmise that the increased food intake by the Hpa-tg
mice is a compensatory phenomenon, secondary to the increased
use of fat as energy source [26,27].
The various phenotypes resulting from genetic perturbation of
the melanocortin signaling system (Fig. 5) largely conform to our
hypothesis that heparanase modulates energy balance via the
melanocortin system, by compromising the AgRP—syndecan-3
interaction at the MC4R. The obese phenotypes seen in mice
lacking MC4R [8] or over-expressing either AgRP or syndecan-1
[10,11,16] resemble that of Hpa-ko mice. Both the MC4R
knockouts [28,29] and heparanase knockouts (Fig. 1C) react by
increasing food intake when challenged with a high-fat diet.
Conversely, the syndecan-3 knockout and AgRP-deficient mice
display lean phenotypes [11,17] similar to the Hpa-tg mice.
The Hpa-tg mice used in this study differ from those described in
a previous report, characterized by significantly reduced food intake
and body weight compared to controls [22]. However, subsequent
examination of these mice revealed a defective intestinal barrier and
leakage of nutrients in the intestine [30]. Intestinal malfunction with
nutrient leakage presumably confounds metabolic phenotype
analysis. The mice used in the present work were from a different
founder derived from the same construct [22], and were back-
crossed to yield a pure genetic background (C57BL/6J). They had
no apparent intestinal problems, most likely due to the low level of
overexpression of heparanase in the intestinal system. However, this
mouse strain showed more prominent heparanase expression in the
brain (Fig. S1).
Human genetic data and murine studies have implicated
MC4R with energy balance regulation in the CNS, hence a
potential target for treatment of obesity and eating disorders
[31,32,33]. Mutations in the MC4R are the most common cause
of monogenic childhood obesity and the severity of obesity can be
quantitatively correlated to the impairment of signaling [12,34].
Moreover, several polymorphisms close to the MC4R gene were
associated with BMI in recent genome-wide association studies
[35,36,37]. The receptor apparently has a key role in coordinating
afferent messages from the periphery and regulatory signals in
control of food intake as well as energy expenditure. Our data
indicate that heparanase acts as a negative modulator of AgRP
signaling at MC4R, through cleavage of HS chains that are
constituents of syndecan-3. This mechanism, along with previously
proposed, modulated shedding of syndecan-3 ectodomain
[13,16,17,18], constitutes a novel signaling system that will help
improve our understanding of obesity and its causes.
Materials and Methods
Mice
Male mice were used throughout the study. Heparanase
overexpressing (Hpa-tg) mice were essentially as described in
[22], except that the mice used in the present study were from a
different founder and were backcrossed (610) to C57BL/6
background. Heparanase cDNA was expressed under the chicken
ß-actin promoter with a CMV-IE enhancer, followed by a rabbit
ß-globin poly-adenylation site. The Hpa-ko mice were described in
[21]. The genotypes of the mice were determined by PCR as
described [21,22]. MC4R-ko (B6;129S4-Mc4rtm1Lowl/J) mice [38]
were purchased from The Jackson Laboratories (Maine, USA) and
were further bred and raised at the local animal facility
(Gothenburg University). For genotyping a three-primer touch-
down PCR was used (Scandinavian Gene Synthesis AB, Ko ¨ping,
Sweden). All MC4R-ko mice were of mixed background (C57BL/
129SV) and we therefore used only siblings as controls. C57BL/6J
mice were purchased from Taconic, Denmark.
Mice were maintained on a 12-hour light, 12-hour dark
schedule (lights on at 7 am). Food and water were available ad
libitum except where otherwise indicated. Standard protocols of
laboratory animal care were followed. The age of mice is indicated
in connection with description of experiments. The experiments
Figure 5. Proposed effects of heparanase on MC4R signaling. HS chains of a cell-surface HSPG serve as co-receptors for AgRP, and at the
same time preclude access of a-MSH to the MC4R. (Left panel) In the absence of heparanase (Hpa-ko) the HS chains remain intact, resulting in
continuous AgRP-induced activation of MC4R, thus promoting food consumption, fat accumulation, and a positive energy balance. Under these
conditions a-MSH signaling is severely restricted. (Right panel) HS chains are degraded by overexpressed heparanase (Hpa-tg), thus rendering the
MC4R accessible to a-MSH, whereas AgRP devoid of its HS co-receptor is unable to engage the MC4R and thus remains inactive. This setting explains
the acute effects of ICV-injected heparanase that lead to transient yet drastic reduction in feeding. However, it is also compatible with the long-term
effects of transgenic heparanase expression that shift energy balance toward increased loss of body fat and compensatory up-regulation of appetite.
doi:10.1371/journal.pone.0034313.g005
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University, Sweden (ID numbers: 211/08, 308/06 and 66/07).
Genotyping
Genomic DNA was isolated from tail biopsies and was purified
using ‘‘HotSHOT’’ genomic DNA preparation [39]. Primers for
Hpa-ko: Neo U-59-gaggctattcggctatgactg-39 and Neo L-59-aggag-
caaggtgagatgaca-39; Hspe U-59-cgttcctgtccatcaccatc-39 and Hspe L-
59- aggctccagacaaagtgctaa-39; For Hpa-tg: Primers were as in [22].
For MC4R-ko: common MC4r#15 9-gcagtacagcgagtctcagg -39,
mutant MC4r#25 9-gtgcaagtgcaggtgccag-39 and wild type
MC4r#35 9-ctccaacaggcttatgacacc-39, yielding a band of 500 bp
(mutant) and a band of 400 bp (wildtype).
Analysis of protein and gene expression
For gene expression, the brains of the mice (12–18 weeks old)
were dissected and total RNA was extracted from hypothalamus.
Q-PCR was applied using the primers shown in Table S1. The
data were normalized using the mRNA level of GAPDH from
each sample. For immunohistochemical staining, the brain
sections were stained with anti-heparanase antibody (733) and
counter-stained with H&M as described previously [22].
Diets and food consumption
High-fat diet, HFD (D12492; 60% fat, 20% protein, 20%
carbohydrate by calories, 5.24 kcal/g), and low-fat diet, LFD
(12450B; 10% fat, 20% protein, 70% carbohydrate by calories,
3.85 kcal/g) were purchased from Research Diets Inc. (New
Brunswick, USA). Normal chow (4% fat, 16.5% protein, 58%
carbohydrate by calories, 2.99 kcal/g) was provided by the animal
facility for routine maintenance (product number R34; Lantma ¨n-
nen, Stockholm, Sweden). Food intake was measured manually,
involving weighing of pre-weighed food pellets at times indicated.
Intracerebroventricular heparanase injections
Recombinantheparanaseforinjectionexperimentswasgenerated
usingsingle-chainGS3activeheparanasegeneconstruct,comprising
the 8 and 50 kDa heparanase heterodimer (8+50), kindly provided
by Dr. Christian Steinkuhler (IRMB/Merck Research Laboratories,
Pomezia, Italy). The recombinant protein was purified to homoge-
neity (crystallization grade) from the conditioned medium of
baculovirus-infected cells [40]. GS3 active heparanase was assayed
forthe presenceofbacterial endotoxinbyBiological Industries,using
the gel-clot technique (Limulus amebocyte lysate, LAL test) and was
found to contain ,10 pg/ml endotoxin [41].
For ICV surgery, mice (6–8 weeks old; C57BL/6J) were
anaesthetized using isofluran (induction 4%, maintenance 2–3%;
air flow, 260 ml/min) and then placed in a stereotactic frame.
Holes through the skull were made using a dentist drill, one for a
steel guide cannula (AG-8, code 806302 from Agntho’s, Lidingo ¨,
Sweden) that was implanted projecting to the lateral ventricle
using stereotactic co-ordinates (0.94 mm posteriorly from bregma
and down 1 mm) and one for a stabilizing screw (Agntho’s). The
cannulae were held in position by dental cement (Dentalon,
Agntho’s, fluid 7509, powder 7508) attached to the stabilizing
screw. Saline (approximately 500 mL/mouse) was given subcuta-
neously for hydration and Rimadyl (2.5 mg/kg mouse) for
analgesic was administered intraperitoneally. After 5–6 days of
recovery on normal chow in individual cages the mice were fasted
for 16 h over-night before ICV injections. Food consumption and
weight regain were recorded as described in the results.
Recombinant heparanase (1.4 mg/mL) in vehicle (20 mM MES,
0.15 M NaCl, pH 6.0) was injected (1 mL/min, total 1 mL) using
CMA pumps (CMA Microdialysis AB, Solna, Sweden) and
Hamilton syringes (Genentec, Va ¨stra Fro ¨lunda, Sweden) connect-
ed to injection cannulae (30G, AMI-9.5; Agntho’s). The vehicle
was used as a control. Food intake was measured at the time points
indicated. To check placement of needle, trypan blue was injected
into the guide cannulae after the experiment followed by dissection
of the brains.
Energy consumption, respiratory quotient and body
composition
Mice at varied ages were used in the different experiments (see
legends to figures); however, wt and transgenic mice in each
experiment were invariably of similar age. Indirect calorimetry
was performed using the INCA systems (Somedic, Ho ¨rby,
Sweden). Mice were placed individually in metabolic chambers
2 hr before start of measurement for adaptation, and were then
maintained in the chambers for 16–20 hr with ad libitum access to
food and water. Oxygen consumption and carbon dioxide release
were measured at 2 min intervals. Data were analysed by
calculating areas under curves followed by two-tailed independent
t-tests. Body composition was determined by dual energy X-ray
absorptiometry (DEXA) using a Lunar PIXImus (GE Lunar,
Madison, WI, USA). Body length was measured on sedated mice
with a ruler from nose to anus.
Statistical procedures
Data were analysed using independent two-tailed t-test and two-
way analysis of variance (ANOVA) using the SPSS program
(SPSS, Chicago, IL, USA). All data presented are means 6 SEM.
P values reported are from independent two-tailed t-tests unless
otherwise stated.
Supporting Information
Figure S1 Immunohistochemical display of human heparanase
expression in Hpa-tg mouse brain. Brain sections were stained with
anti-heparanase antibody (733; red). The heparanase positive cells
in the hypothalamic nucleus are indicated by arrows.
(TIF)
Figure S2 Faecal energy contents determined by bomb
calorimetry. Faeces was collected from wt (n=4) and Hpa-tg
(n=5) mice (16 months old) and submitted to bomb calorimetry,
(C 5000, IKAHWerke GmbH & Co. KG, Germany).
(TIFF)
Figure S3 Expression of Synd3, Pomc and AgRP genes in
hypothalamus.The brains of mice (24–28 weeks old) were
dissected, and RNA was extracted from the hypothalamus and
analyzed for gene expression by Q-PCR, as described in Methods.
(TIF)
Table S1 Primers used in quantitative PCR.
(DOCX)
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